Issues
-
Cover Image
Cover Image
Inheritance of a germ line mutation in the BRCA1 or BRCA2 (BRCA1/2) gene confers early onset breast and ovarian cancer risk that is many times higher than that in the general population. Gao and colleagues report that a polymorphism in tumor suppressor gene RASSF1A (A133S) also confers an increased risk of developing breast cancer in Caucasian women. Importantly, they found that the average age at breast cancer diagnosis for BRCA1/2 mutation carriers with A133S is six years earlier than in individuals with wild-type RASSF1A. They hypothesized that RASSF1A modifies the risk of breast cancer in BRCA1/2 mutation carriers.
This finding provides more evidence of the importance of the RASSF1A tumor suppressor gene as the A133S variant has been shown to have lost functional activity compared to wild-type RASSF1A. It also suggests the need for a large-scale study to validate the effect of A133S in the development of breast and other types of cancer. If confirmed, RASSF1A A133S could be developed as a molecular biomarker for refining cancer risk estimates for women at higher risk for breast cancer. Women with a BRCA1/2 mutation and wild-type RASSF1A (A133S) might use such information to aid decisions regarding timing of risk-reducing interventions, such as prophylactic surgery or chemoprevention. For details, see the article by Gao and colleagues on page 22 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Editorial
Reviews
Perspectives in Cancer Research
Priority Reports
RASSF1A Polymorphism A133S Is Associated with Early Onset Breast Cancer in BRCA1/2 Mutation Carriers
Molecular Biology, Pathobiology, and Genetics
Cell, Tumor, and Stem Cell Biology
Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
Experimental Therapeutics, Molecular Targets, and Chemical Biology
A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
Capsiate, a Nonpungent Capsaicin-Like Compound, Inhibits Angiogenesis and Vascular Permeability via a Direct Inhibition of Src Kinase Activity
Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells
Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells
Immunology
Endocrinology
Clinical Research
Epidemiology
Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.